Literature DB >> 11380602

Bone marrow stromal dysfunction in mice administered cytosine arabinoside.

Z Ben-Ishay1, V Barak.   

Abstract

OBJECTIVE: The aim of the study was to investigate ex-vivo the bone marrow (BM) stroma of mice under conditions of low- and high-dose cytosine arabinoside (Ara-C), a cycle-specific drug (S-phase) and to assess possible stromal damage, apart from the killing of hematopoietic cells. Stroma consists of mesenchymal elements generally not in the cell cycle; therefore it could not be a target for the killing effect of Ara- C.
MATERIALS AND METHODS: The stromal function was studied by the following: the incidence of stromal stem cells, i.e. CFU-F; formation of stromal layers under growth conditions of long-term culture (LTC) followed by irradiation and overlayering of test cells in contact and non-contact co-cultures; subsequent culture of the test cells in a semi-solid medium to assay the incidence of hyperproliferative potential cells (HPPC); production of GM-CSF, IL-3, IL-4, IL-6 and IFNgamma in the conditioned medium (CM) of confluent stromal layers. All tests and assays were carried out on BM specimens, 1-4 d after Ara-C administration and on controls.
RESULTS: Low-dose Ara-C induces a marked decrease of CFU-F, compensated by cycle induction of pre-CFU-F, young-type stromal stem cells. High-dose Ara-C causes a CFU-F decrease to almost zero level. The time length to layer confluency is normal after low-dose Ara-C ( approximately 10 d) and prolonged after a high dose ( approximately 30 d). The confluent layers from mice receiving low- or high-dose Ara-C support hematopoiesis adequately. Among the growth factors and cytokines assayed, only IL-6 is detected in CM layers. IL-6 decreases after a low dose of Ara-C and increases after a high dose. The cause of IL-6 fluctuations is yet to be investigated. It is, however, evident that IL-6 is not an essential factor in support of hematopoiesis.
CONCLUSIONS: Taken together, the current study in mice indicates that Ara-C administration, in particular a high dose, induces bone marrow stromal damage and/or disfunction. The long period of time to reach layer confluency after a high Ara-C dose might reflect the in-vivo situation of slow stromal regeneration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380602     DOI: 10.1034/j.1600-0609.2001.066004230.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

Authors:  Yogen Saunthararajah; Mikkael Sekeres; Anjali Advani; Reda Mahfouz; Lisa Durkin; Tomas Radivoyevitch; Ricki Englehaupt; Joy Juersivich; Kathleen Cooper; Holleh Husseinzadeh; Bartlomiej Przychodzen; Matthew Rump; Sean Hobson; Marc Earl; Ronald Sobecks; Robert Dean; Frederic Reu; Ramon Tiu; Betty Hamilton; Edward Copelan; Alan Lichtin; Eric Hsi; Matt Kalaycio; Jaroslaw Maciejewski
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

2.  Deregulation of the CXCL12/CXCR4 axis in methotrexate chemotherapy-induced damage and recovery of the bone marrow microenvironment.

Authors:  Kristen R Georgiou; Michaela A Scherer; Tristan J King; Bruce K Foster; Cory J Xian
Journal:  Int J Exp Pathol       Date:  2012-01-05       Impact factor: 1.925

3.  Cytosine arabinoside reduces the numbers of granulocyte macrophage colony forming cells (GM-CFC) and high proliferative potential colony forming cells (HPP-CFC) in vivo in mice.

Authors:  Stanley Teleka; Alexander Chijuwa; Edward Senga; John E Chisi
Journal:  Malawi Med J       Date:  2011-12       Impact factor: 0.875

4.  Zinc oxide nanoparticles promote the aging process in a size-dependent manner.

Authors:  Mahla Deylam; Effat Alizadeh; Manizheh Sarikhani; Marzie Hejazy; Masoumeh Firouzamandi
Journal:  J Mater Sci Mater Med       Date:  2021-09-30       Impact factor: 3.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.